NPS Pharmaceuticals Inc (NPSP)

45.97
0.01 0.02
Prev Close 45.96
Open 45.96
Day Low/High 45.95 / 45.99
52 Wk Low/High 22.11 / 46.01
Volume 9.49M
Avg Volume 4.75M
Exchange
Shares Outstanding 108.58M
Market Cap 4.99B
EPS -0.08
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

We took advantage of some buying opportunities this week and added shares to three of our model portfolio positions.

NPS Pharmaceuticals To Present At Upcoming Conferences

NPS Pharmaceuticals To Present At Upcoming Conferences

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the 15 th Annual Bio CEO & Investor Conference in New York on Monday, February 11, 2013 at 10:30 a.

Stocks Under $10 Weekly Summary

During a week filled with earnings action and economic reports, we booked some gains in one model portfolio name.

New Peer-reviewed Publication Offers Guidance For Integrating Gattex® (Teduglutide [rDNA Origin]) For Injection Into Management Of Short Bowel Syndrome

New Peer-reviewed Publication Offers Guidance For Integrating Gattex® (Teduglutide [rDNA Origin]) For Injection Into Management Of Short Bowel Syndrome

The Journal of Parenteral and Enteral Nutrition recently published clinical considerations and best-practice recommendations for introducing Gattex ® (teduglutide [rDNA origin]) for injection into the management...

Stocks Under $10 Weekly Summary

With major U.S. indices near all-time highs, we will continue to scour the universe of low-dollar stocks for buying opportunities.

Stocks Under $10 Weekly Summary

Amid an options expiration week that saw volatility in U.S. stocks drop, we added a new name to the model portfolio.

Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma

Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

Biotech Stock Lessons From 2013 J.P. Morgan Healthcare Confab

Biotech Stock Lessons From 2013 J.P. Morgan Healthcare Confab

The best and worst biotech and drug companies to emerge from last week's investor conference.

Stocks Under $10 Weekly Summary

Earnings season kicked off this week amid low market volatility, and we closed out one model portfolio position.

Cramer's Top Stock Picks: NPSP BAC EXAS

Cramer's Top Stock Picks: NPSP BAC EXAS

NPS Pharmceuticals and Exact Sciences are two good plays in health while Bank of America should outshine other banks, Cramer said.

Cramer's 'Mad Money' Recap: Safe Harbors for Investment

Cramer's 'Mad Money' Recap: Safe Harbors for Investment

On down days investors need safe places, said Cramer, who kicked off a weeklong series of investing trends for 2013.

Stocks Under $10 Weekly Summary

Stocks kicked off 2013 with a bang, and several model portfolio delivered double-digit percentage gains this week.

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

NPS Pharma: Controversy Over Super-Expensive Orphan Drug Prices

NPS Pharma: Controversy Over Super-Expensive Orphan Drug Prices

A debate about NPS Pharma, Gattex and the sustainability of orphan drug pricing with Forbes' Matt Herper

Updating a Pair of Positions

This pharmaceutical name is about to launch an important product and our largest holding continues to increase in value.

NPS Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

NPS Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 31 st Annual J.

NPS Pharmaceuticals To Host Conference Call To Discuss FDA Approval Of Gattex® (teduglutide [rDNA Origin]) For Injection For The Treatment Of Adult Short Bowel Syndrome

NPS Pharmaceuticals To Host Conference Call To Discuss FDA Approval Of Gattex® (teduglutide [rDNA Origin]) For Injection For The Treatment Of Adult Short Bowel Syndrome

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will host a conference call to discuss its commercialization plan for Gattex, including the cost of therapy, today at 5:00 p.

13 Biotech Stock Predictions for 2013

13 Biotech Stock Predictions for 2013

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.

Stocks Under $10 Weekly Summary

It was a quiet week for the model portfolio, but we would consider adding to our positions on the next market pullback.

NPS Pharmaceuticals Signs Agreements With Leading Specialty Home Infusion Providers To Support Distribution And Home-based Clinical Care Services For Gattex®

NPS Pharmaceuticals Signs Agreements With Leading Specialty Home Infusion Providers To Support Distribution And Home-based Clinical Care Services For Gattex®

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that it has established a ...

Stocks Under $10 Weekly Summary

Amid a volatile week of trading, we trimmed one model portfolio name and added shares to two others.

FDA Approves Gattex® (teduglutide [rDNA Origin]) For Injection For The Treatment Of Adult Short Bowel Syndrome

FDA Approves Gattex® (teduglutide [rDNA Origin]) For Injection For The Treatment Of Adult Short Bowel Syndrome

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.

Increasing an Pharmaceutical Holding

In the midst of today's broad market weakness, we will put cash to work by adding shares to this biotech name.

Stocks Under $10 Weekly Summary

As we begin to position the model portfolio for 2013, we added shares to one position this week.

The Next Big Thing in Biotech: FDA Decisions

The Next Big Thing in Biotech: FDA Decisions

Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.

Stocks Under $10 Weekly Summary

It was a volatile week for the market but a quiet one for the model portfolio, as we continued to search for new names.

Stocks Under $10 Weekly Summary

It was a quiet week for the model portfolio, but we will continue to monitor the market's volatility for opportunities.

NPS Pharmaceuticals Announces Publication Of Pivotal Phase 3 Study Of Gattex® (teduglutide) In Short Bowel Syndrome-Intestinal Failure Patients

NPS Pharmaceuticals Announces Publication Of Pivotal Phase 3 Study Of Gattex® (teduglutide) In Short Bowel Syndrome-Intestinal Failure Patients

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that its Phase 3 study of Gattex ...

NPS Pharmaceuticals To Present At Deutsche Bank BioFEST Conference

NPS Pharmaceuticals To Present At Deutsche Bank BioFEST Conference

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 2012 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 4, 2012 at 10:10 a.

Stocks Under $10 Weekly Summary

As the post-election selloff continued this week, we sold some shares of one model portfolio name and added to four others.